GT Biopharma, Inc. (GTBP)

GT Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2.53	3.95	1.08	5.67	8.97	5.3
Short-Term Investments	-	-	12.89	10.84	23.01	-
Cash & Short-Term Investments	2.53	3.95	13.97	16.51	31.98	5.3
Cash Growth	-60.61%	-71.72%	-15.36%	-48.38%	503.72%	18817.86%
Prepaid Expenses	0.94	0.19	0.08	0.05	0.19	0.36
Restricted Cash	0.09	0.09	-	-	-	-
Total Current Assets	4.32	4.23	14.06	16.56	32.17	5.66
Property, Plant & Equipment	-	-	0.05	0.17	-	-
Other Long-Term Assets	-	-	-	0.01	-	-
Total Assets	4.32	4.23	14.11	16.74	32.17	5.66
Accounts Payable	0.77	3.85	4.33	3.14	8.19	2.24
Accrued Expenses	0.4	1.8	1.2	1.67	1.9	6.13
Short-Term Debt	-	-	-	-	0.03	26.33
Current Portion of Leases	-	-	0.06	0.11	-	-
Other Current Liabilities	0.15	0.25	1.05	0.02	0.14	0.38
Total Current Liabilities	1.32	5.9	6.63	4.94	10.26	35.09
Long-Term Leases	-	-	-	0.06	-	-
Total Liabilities	1.32	5.9	6.63	5	10.26	35.09
Common Stock	0.01	0	0	0.03	0.03	0.01
Additional Paid-In Capital	703.77	693.55	689.54	686.17	674.35	566.36
Retained Earnings	-700.78	-695.23	-682.07	-674.47	-653.58	-595.8
Comprehensive Income & Other	-	-	-	-	1.11	-
Total Common Equity	3	-1.67	7.48	11.73	21.91	-29.44
Shareholders' Equity	3	-1.67	7.48	11.73	21.91	-29.43
Total Liabilities & Equity	4.32	4.23	14.11	16.74	32.17	5.66
Total Debt	-	-	0.06	0.17	0.03	26.33
Net Cash (Debt)	2.53	3.95	13.91	16.33	31.95	-21.04
Net Cash Growth	-60.61%	-71.60%	-14.82%	-48.87%	-	-
Net Cash Per Share	0.89	2.08	10.32	15.38	34.04	-143.92
Filing Date Shares Outstanding	10.64	2.23	1.38	1.23	1.07	0.95
Total Common Shares Outstanding	6.05	2.23	1.38	1.09	1.07	0.17
Working Capital	3	-1.67	7.42	11.62	21.91	-29.43
Book Value Per Share	0.50	-0.75	5.41	10.76	20.50	-169.23
Tangible Book Value	3	-1.67	7.48	11.73	21.91	-29.44
Tangible Book Value Per Share	0.50	-0.75	5.41	10.76	20.50	-169.23

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q